References
- Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;19:857-61. https://doi.org/10.1097/00004872-200105000-00004
- Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005;19:149-54. https://doi.org/10.1038/sj.jhh.1001785
- Borekci A, Gur M, Turkoglu C, et al. Neutrophil to lymphocyte ratio predicts left ventricular remodeling in patients with ST elevation myocardial infarction after primary percutaneous coronary intervention. Korean Circ J 2016;46:15-22. https://doi.org/10.4070/kcj.2016.46.1.15
- Dehghani MR, Rezaei Y, Fakour S, Arjmand N. White blood cell count to mean platelet volume ratio is a prognostic factor in patients with non-ST elevation acute coronary syndrome with or without metabolic syndrome. Korean Circ J 2016;46:229-38. https://doi.org/10.4070/kcj.2016.46.2.229
- Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006;188:450-4. https://doi.org/10.1016/j.atherosclerosis.2005.11.013
- Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 2003;26:2622-7. https://doi.org/10.2337/diacare.26.9.2622
- Colston JT, Boylston WH, Feldman MD, et al. Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload. Biochem Biophys Res Commun 2007;354:552-8. https://doi.org/10.1016/j.bbrc.2007.01.030
- Woldbaek PR, Sande JB, Stromme TA, et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 2005;289:H708-14. https://doi.org/10.1152/ajpheart.01179.2004
- Vilarrasa N, Vendrell J, Maravall J, et al. IL-18: relationship with anthropometry, body composition parameters, leptin and arterial hypertension. Horm Metab Res 2006;38:507-12. https://doi.org/10.1055/s-2006-949122
- Thorand B, Kolb H, Baumert J, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/ KORA Augsburg study, 1984-2002. Diabetes 2005;54:2932-8. https://doi.org/10.2337/diabetes.54.10.2932
- Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2015;28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
- Blankenberg S, Luc G, Ducimetiere P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003;108:2453-9. https://doi.org/10.1161/01.CIR.0000099509.76044.A2
- Pickering TG, White WB. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008;2:119-24. https://doi.org/10.1016/j.jash.2008.04.002
- Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage. J Hypertens 2008;26:1919-27. https://doi.org/10.1097/HJH.0b013e32830c4368
- Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2008;26:1290-9. https://doi.org/10.1097/HJH.0b013e3282f97854
- Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007;370:1219-29. https://doi.org/10.1016/S0140-6736(07)61538-4
- Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008;51:55-61. https://doi.org/10.1161/HYPERTENSIONAHA.107.100727
- Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens 2009;27:2121-58. https://doi.org/10.1097/HJH.0b013e328333146d
- Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6. https://doi.org/10.1001/jama.292.19.2350
- Blacher J, Evans A, Arveiler D, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME study. J Hum Hypertens 2010;24:19-26. https://doi.org/10.1038/jhh.2009.34
- Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 2009;6:192-9.
- Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res 2006;71:216-25. https://doi.org/10.1016/j.cardiores.2006.02.033
- Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 2005;96:1064-71. https://doi.org/10.1161/01.RES.0000168210.10358.f4
- Doi T, Sakoda T, Akagami T, et al. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol 2008;295:H1279-H87. https://doi.org/10.1152/ajpheart.00148.2008
- Rumantir MS, Jennings GL, Lambert GW, Kaye DM, Seals DR, Esler MD. The 'adrenaline hypothesis' of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension. J Hypertens 2000;18:717-23. https://doi.org/10.1097/00004872-200018060-00009
- Chandrasekar B, Marelli-Berg FM, Tone M, Bysani S, Prabhu SD, Murray DR. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun 2004;319:304-11. https://doi.org/10.1016/j.bbrc.2004.04.185
- Mistry P, Reid J, Pouliquen I, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects. Int J Clin Pharmacol Ther 2014;52:867-79. https://doi.org/10.5414/CP202087
- Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 2006;31:109-16. https://doi.org/10.1007/BF03191127
- O'Brien LC, Mezzaroma E, Van Tassell BW, et al. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med 2014;20:221-9.
- Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-57. https://doi.org/10.1084/jem.20011022
Cited by
- NLR-A Simple Indicator of Inflammation for the Diagnosis of Left Ventricular Hypertrophy in Patients with Hypertension vol.61, pp.2, 2020, https://doi.org/10.1536/ihj.19-138
- Changes in blood levels of IL1 family cytokines in patients with essential hypertension after having COVID-19 vol.2021, pp.2021, 2017, https://doi.org/10.24075/brsmu.2021.026
- Plasma S1P (Sphingosine-1-Phosphate) Links to Hypertension and Biomarkers of Inflammation and Cardiovascular Disease: Findings From a Translational Investigation vol.78, pp.1, 2017, https://doi.org/10.1161/hypertensionaha.120.17379